Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2015-12-02 Regulatory Filings
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a 'PRESS RELEASE – FOR IMMEDIATE RELEASE' announcing a collaboration between IntegraGen and investigators of the FIRE-3 clinical trial regarding a biomarker study in metastatic colorectal cancer. This type of announcement, detailing ongoing research, partnerships, or general corporate news that doesn't fit specific financial reporting categories (like 10-K, ER, or DIV), typically falls under general regulatory announcements or investor relations material. Since it is not a formal financial report (like IR or 10-K), nor a specific management change (MANG) or dividend notice (DIV), the most appropriate general category for corporate news releases that don't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous official announcements.
2015-12-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE – DIFFUSION IMMÉDIATE" (Press Release – Immediate Release) and announces a collaboration regarding the validation of a biomarker (miR-31-3p) in metastatic colorectal cancer, referencing a Phase 3 clinical trial (FIRE-3). This format, announcing a specific business development, scientific update, or partnership, is characteristic of a general press release. Since there is no specific regulatory filing code (like 10-K, 10-Q, DEF 14A) mentioned, and it is not a transcript (CT), earnings release (ER), or a formal report (AR, IR), the most appropriate general category for a non-standard, immediate corporate announcement is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/corporate news not covered by other specific codes. The length (4017 chars) is substantial enough to be the primary announcement itself, not just a notice of publication (RPA).
2015-12-02 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE – POUR DIFFUSION IMMEDIATE" (Press Release – For Immediate Release) and details a partnership achievement between Gustave Roussy and IntegraGen regarding genomic sequencing for clinical research. This format, announcing operational milestones and scientific progress rather than mandatory financial disclosures (like 10-K, ER, or IR), strongly suggests a general corporate or operational announcement. Since it is not a specific regulatory filing (like DIRS, DIV, CAP, etc.) and is not a transcript (CT) or a formal presentation (IP), the most appropriate general category for a press release announcing operational news is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous corporate announcements that don't fit elsewhere, although 'RPA' (Report Publication Announcement) is sometimes used for announcements, this document is reporting an achievement, not the publication of a formal report. Given the context of a press release announcing operational success, RNS is the best fit among the provided options as a general corporate communication.
2015-11-17 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is titled 'COMMUNIQUÉ DE PRESSE - DIFFUSION IMMÉDIATE' and presents 'Résultats du 1er semestre 2015' (Results for the first half of 2015). It contains key financial highlights (revenue, operating result, net result) and detailed tables for the Income Statement and Balance Sheet for the six-month period ending June 30, 2015. This structure—a press release summarizing period-specific financial performance—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) nor a comprehensive Interim Report (IR) in the sense of a full regulatory filing, but rather the initial announcement of the results. Since it focuses on the period results announcement, ER is the most appropriate code. The length (13,584 chars) is substantial, indicating it is more than just a brief announcement of a report's availability (RPA/RNS). H1 2015
2015-10-02 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE - DIFFUSION IMMÉDIATE" and announces the "Chiffre d'affaires du 1er semestre 2015" (Revenue for the first half of 2015). This content, focusing on key financial highlights for a specific period (H1 2015) immediately following the period end, aligns perfectly with the definition of an Earnings Release (ER). Although it mentions that the company will publish its full semi-annual results on October 6th, this document itself is the initial announcement of the results/highlights, not the announcement of the publication date (RPA) or the full report itself (IR). The length (5184 chars) is substantial enough to contain more than just a brief announcement, but its structure is that of a press release summarizing performance metrics. H1 2015
2015-07-10 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE - DIFFUSION IMMÉDIATE" (Press Release - Immediate Release) and announces positive study results presented at the 2015 American Society of Clinical Oncology (ASCO) congress regarding a biomarker (miR-31-3p) for metastatic colorectal cancer treatment. This is a typical announcement summarizing key findings and their implications, rather than the full financial report (10-K, IR) or a transcript of a call (CT). Since it is an announcement of scientific/clinical progress and results, it fits best under the general category for regulatory/corporate announcements that aren't strictly financial results or management changes. Given the options, it is a general corporate announcement. It is not an Earnings Release (ER) as it focuses on clinical trial data, not quarterly financial performance. It is not an Investor Presentation (IP) as it is a press release format. It is not a Regulatory Filing (RNS) in the sense of a mandatory SEC/AMF filing, but it is a public announcement. However, since it details specific scientific/clinical updates and is not a standard financial report, it is most closely aligned with a general corporate update. Given the specific definitions, and since it is a press release announcing scientific progress, it does not fit perfectly into the financial categories. It is a general corporate announcement. In the absence of a specific 'Clinical Update' or 'Research Announcement' category, and noting that it is a formal announcement of corporate news, the closest fit among the provided options for non-financial, non-management, non-legal updates is often the general Regulatory Filings (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but this is a press release. Since it is a formal announcement of corporate news that doesn't fit the other specific categories (like ER, 10-K, MANG, LTR), RNS serves as the best general regulatory/corporate announcement fallback. FY 2015
2015-06-01 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.